Biotech Kriya snags $80.5M to push gene therapy beyond rare disease

Many gene therapies are designed for monogenic diseases—that is, ailments caused by a defect in a single gene. But these treatments are just “scratching the surface” of what gene therapy can accomplish. Enter Kriya Therapeutics, which raised $80.5 million to develop gene therapies for more complex—but more common—diseases like diabetes.